Ultralife Earnings Reports

Ultralife Corporation posted a quarterly net loss despite higher sales, as one-time charges and manufacturing inefficiencies weighed on profitability.

Ultralife Corporation reported a challenging second quarter in 2025, with total revenue increasing by 13.0% to $48.6 million due to the Electrochem acquisition. However, GAAP EPS decreased significantly to $0.05 from $0.18 in the prior year, and operating income fell to $2.3 million from $3.9 million, primarily due to a 57.2% decline in Communications Systems sales and pressures on gross profit from product mix, tariffs, and freight costs.

Ultralife Corporation delivered a strong first quarter with a 21% year-over-year revenue increase, driven by robust organic growth in Battery & Energy Products government/defense sales, which compensated for delays in Communications Systems orders. The company focused on improving gross margin and reducing inventory, while continuing strategic investments and integrating the Electrochem acquisition.

Ultralife Corporation posted Q4 2024 revenue of $43.9 million, down slightly year-over-year. Profitability metrics, including net income and operating income, decreased, largely due to one-time costs related to the Electrochem acquisition and a sharp decline in Communications Systems revenue. Adjusted EBITDA and gross margin also declined compared to the prior year.

Ultralife Corporation reported a decrease in revenue for the third quarter of 2024, with sales of $35.7 million compared to $39.5 million in the same period last year. The Battery & Energy Products segment saw a slight increase in sales, while the Communications Systems segment experienced a significant decrease. Operating income and net income also declined compared to the previous year.

Ultralife Corporation reported a slight increase in revenue and improved gross profit for the second quarter of 2024. The company saw growth in Battery & Energy Products sales, particularly in government/defense and medical battery sectors. Debt was reduced by over 50%.

Ultralife Corporation reported a strong first quarter with a 31.4% increase in sales, driven by growth in the medical market. Gross profit and operating income improved significantly, leading to GAAP EPS of $0.18 compared to a loss in the previous year. The company is optimistic about sustaining profitable growth and generating cash flow.

Ultralife Corporation reported a strong fourth quarter with a 23.4% increase in sales, driven by growth in both government/defense and commercial sectors. The company's operating income significantly improved, and adjusted EPS turned positive. Battery & Energy Products saw growth in commercial sales, particularly in medical batteries, while Communications Systems benefited from shipments to defense contractors.

Ultralife Corporation reported strong Q3 2023 results, with sales up 18.8% year-over-year to $39.5 million. Operating income significantly improved to $2.1 million from a loss of $0.6 million in the same quarter last year. Adjusted EPS was $0.10 compared to a loss of $0.03 in Q3 2022. The company's backlog remains strong at $101.1 million.

Ultralife Corporation reported a 32.9% year-over-year increase in sales to $42.7 million for the second quarter of 2023. Operating income significantly improved to $3.7 million, and adjusted EPS reached $0.29. The company's backlog increased to $110.9 million, driven by strong demand from government/defense and medical customers.

Ultralife Corporation reported a revenue increase of 5.1% to $31.9 million, with breakeven operating income for Q1 2023. The cybersecurity attack negatively impacted the operating results, however, gross margin improved through price realization.

Ultralife Corporation reported a significant increase in revenue and a favorable swing in operating profit for Q4 2022 compared to Q4 2021. Revenue increased by 51.9%, driven by growth in both government/defense and commercial sales. The company's backlog reached a record high, and gross margin improved compared to the previous quarter.

Ultralife Corporation reported a revenue of $33.2 million for the third quarter ended September 30, 2022, representing a 52.7% increase compared to the same period last year. The company experienced an operating loss of $0.6 million and an adjusted EBITDA of $1.3 million.

Ultralife Corporation reported a 20% year-over-year sales increase driven by the Excell acquisition and strong shipments to core commercial end-markets. The company returned to total profitability despite persistent supply chain constraints and inflationary cost pressures.

Ultralife Corporation reported a revenue increase of 16.9% to $30.4 million, driven by strong order flow and the acquisition of Excell Battery Group. However, the company experienced an operating loss of $0.3 million due to supply chain constraints, input cost inflation, and investments in new product development.

Ultralife Corporation reported a decrease in revenue and operating income for Q4 2021 compared to the same period in 2020. The results were impacted by supply chain challenges, COVID-19 related logistics matters, and acquisition costs related to the Excell Battery Group. Despite these challenges, order flow remained strong and backlog increased.

Ultralife Corporation reported a decrease in revenue and operating income for the third quarter of 2021, with an operating loss of $0.8 million on revenue of $21.8 million. The decline was attributed to supply chain bottlenecks and delayed shipments, particularly impacting the government/defense sector, although commercial sales saw an increase.

Ultralife Corporation reported a decrease in revenue and operating income for the second quarter of 2021 compared to the same period in 2020. Revenue decreased by 6.3% to $26.8 million, and operating income decreased to $1.1 million. Supply chain and logistics challenges impacted shipments and increased freight costs.

Ultralife Corporation reported a slight increase in revenue for Q1 2021, with operating income decreasing compared to the same period last year. The revenue increase was primarily driven by growth in the Battery & Energy Products segment, particularly in medical and government/defense sales, while profitability was affected by start-up costs for new product transitions and investments in engineering and sales resources.

Ultralife Corporation reported a decrease in revenue for the fourth quarter, primarily due to the negative economic impact of the global pandemic. However, the company saw growth in medical and government/defense sales, which partially offset the decline. The company's operating results were in line with internal expectations.

Ultralife Corporation reported a decrease in revenue and operating income for Q3 2020 compared to Q3 2019, with revenue at $24.4 million and operating income at $0.7 million. The company sustained profitability and positive cash flows through end-market diversification and operating discipline, offsetting economic weakness in the oil and gas sector and lower Communications Systems sales with strong medical and government/defense sales.

Ultralife Corporation reported a decrease in revenue and operating income for the second quarter of 2020 compared to the same period in 2019. However, the company's adjusted earnings per share of $0.13 reflects the benefits of end-market diversity and a resilient business model despite business disruptions caused by the pandemic.

Ultralife Corporation reported a substantial increase in revenue and operating income for the first quarter of 2020. Revenue increased by 37% and operating profit increased by 171% compared to the same period last year. The company faced challenges due to COVID-19, including a shutdown in China, but managed to maintain operations and invest in growth initiatives.

Ultralife Corporation reported Q4 2019 results with revenue of $31.0 million and operating income of $2.5 million, compared to $20.9 million and $1.1 million respectively for Q4 2018. The revenue increase was driven by growth in both Battery & Energy Products and Communications Systems segments.